Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In Re: KALOBIOS PHARMACEUTICALS, INC. SECURITIES LITIGATION
Case Number:
5:15-cv-05841
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Fenwick & West
- Fox Rothschild
- Glancy Prongay
- Green & Noblin PC
- Hogan Lovells
- King & Spalding
- Levi & Korsinsky
- Pomerantz LLP
- WilmerHale
Companies
Sectors & Industries:
-
March 22, 2018
Shkreli Cuts $1.5M Deal To End KaloBios Investors' Suit
KaloBios Pharmaceuticals Inc. shareholders asked a California federal judge on Wednesday to approve a $1.5 million deal to resolve claims against former KaloBios CEO Martin Shkreli, marking an end to a securities class action over Shkreli's legal woes.
-
January 23, 2017
KaloBios Investors Take $1.5M Deal But Still Target Shkreli
KaloBios Pharmaceuticals and two executives have agreed to shell out $1.5 million to settle part of a putative securities class action sparked by pharmaceutical executive Martin Shkreli's one-month tenure as KaloBios CEO, ending allegations that they violated securities laws by omitting facts concerning Shkreli's legal woes but not claims against Shkreli.
-
August 17, 2016
Shkreli Seeks Escape From KaloBios Securities Litigation
Pharmaceutical executive Martin Shkreli filed a motion to dismiss a putative securities class action related to his brief tenure at KaloBios Pharmaceuticals on Tuesday, saying the California litigation was sparked by his indictment on securities fraud charges at companies unrelated to his work with KaloBios.